89bio, Inc. (ETNB)
NASDAQ: ETNB · Real-Time Price · USD
8.76
+0.38 (4.53%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.

Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.

The company was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc.
89bio logo
Country United States
Founded 2018
IPO Date Nov 11, 2019
Industry Biotechnology
Sector Healthcare
Employees 70
CEO Rohan Palekar

Contact Details

Address:
142 Sansome Street, Second Floor
San Francisco, California 94104
United States
Phone 415 432 9270
Website 89bio.com

Stock Details

Ticker Symbol ETNB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001785173
CUSIP Number 282559103
ISIN Number US2825591033
Employer ID 83-1114349
SIC Code 2834

Key Executives

Name Position
Rohan Palekar Chief Executive Officer and Director
Quoc Le-Nguyen Chief Technical Officer
Dr. Harry Mansbach M.D. Chief Medical Officer
Ryan Stephen Martins Chief Financial Officer
Francis W. Sarena Chief Operating Officer
Shiva K. Natarajan CPA Senior Vice President of Finance and Principal Accounting Officer
Annie J. Chang M.B.A. Vice President of Investor Relations and Corporate Communications
Amanda Kurihara Vice President of People and Culture
Melissa Abel Senior Vice President of Commercial Strategy
Paul Shin Senior Vice President of Research & Development Operations

Latest SEC Filings

Date Type Title
Nov 18, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Nov 13, 2024 424B5 Filing
Nov 12, 2024 424B5 Filing
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report